Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2014-03-20 Capital/Financing Update
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1, which is used for initial public offerings or other securities registrations under the Securities Act of 1933. It includes detailed information about the company, securities being registered, indemnification of directors and officers, recent sales of unregistered securities, and exhibits such as underwriting agreements and corporate governance documents. The presence of the Form S-1 and the detailed registration information indicates this is a capital raising filing related to securities registration, not a financial report, earnings release, or management discussion. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a certification, so it is not RPA or RNS. Confidence is high due to the clear identification of the form and content.
2014-03-20 English
Regulatory Filings 2014
Regulatory Filings
2014-03-13 English
Capital/Financing Update 2014
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement confidentially submitted to the SEC, dated February 14, 2014, for Histogenics Corporation. It is a draft registration statement for an initial public offering (IPO) under the Securities Act of 1933. The text includes detailed information typical of an IPO prospectus, such as risk factors, use of proceeds, capitalization, dilution, financial information, management discussion and analysis, business description, management and director compensation, principal stockholders, and underwriting details. This type of filing is a registration statement for securities offering, which is a capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or any other report type listed. The document length and content confirm it is the actual registration statement, not just an announcement or certification.
2014-02-14 English
Regulatory Filings 2014
Regulatory Filings
2014-01-06 English
Regulatory Filings 2012
Regulatory Filings
2012-11-26 English
Regulatory Filings 2012
Regulatory Filings
2012-07-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.